Hepatic Impairment clinical trials

Explore recruiting hepatic impairment clinical trials.

Recruiting hepatic impairment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatic Impairment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study About Fazirsiran in People With and Without Liver Problems.

Hungary, Slovakia

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion (SSD) Formulation in Adult Subjects with Impaired Hepatic Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function

Slovakia

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656, an Antisense Inhibitor of Complement Factor B

Slovakia, Germany, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant in Post-menopausal Female Subjects

Bulgaria, Slovakia

Human Pharmacology (Phase I)- Other EU CTIS Study details

A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single 50 mg dose in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.

Bulgaria, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Hepatic Impairment trials by city

Hepatic Impairment in Toronto Hepatic Impairment in Vancouver Hepatic Impairment in Montreal Hepatic Impairment in Calgary Hepatic Impairment in Edmonton Hepatic Impairment in Ottawa Hepatic Impairment in Winnipeg Hepatic Impairment in Quebec City Hepatic Impairment in Hamilton Hepatic Impairment in Kitchener Hepatic Impairment in London Hepatic Impairment in Halifax Hepatic Impairment in New York Hepatic Impairment in Los Angeles Hepatic Impairment in Chicago Hepatic Impairment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease